PURPOSE: Predictive strategies for the treatment efficacy of cetuximab are currently not available for head and neck cancer. We investigated the correlation between the expression of epidermal growth factor receptor (EGFR) ligands and EGFR expression, and the growth inhibitory activity of cetuximab in a panel of head and neck squamous cell carcinoma (HNSCC) cell lines. METHODS: The growth inhibiting effect of cetuximab was measured for eight HNSCC cell lines and correlated with the autocrine production of five EGFR ligands as measured by ELISA, and the mRNA expression of two ligands, as measured by quantitative RT-PCR. EGFR expression was assessed by western blot analysis. RESULTS: There was a good correlation between the expression of four of the EGFR ligands (TGF-α, amphiregulin, epiregulin and epigen) and the growth inhibiting effect of cetuximab. TGF-α had the highest predictive potential but had to be combined with epigen for full prediction. EGFR expression also correlated with cetuximab sensitivity but less clearly. CONCLUSIONS: The results indicate that the expression of several EGFR ligands has to be used to predict sensitivity to cetuximab in HNSCC. This has to be further evaluated in clinical samples.
PURPOSE: Predictive strategies for the treatment efficacy of cetuximab are currently not available for head and neck cancer. We investigated the correlation between the expression of epidermal growth factor receptor (EGFR) ligands and EGFR expression, and the growth inhibitory activity of cetuximab in a panel of head and neck squamous cell carcinoma (HNSCC) cell lines. METHODS: The growth inhibiting effect of cetuximab was measured for eight HNSCC cell lines and correlated with the autocrine production of five EGFR ligands as measured by ELISA, and the mRNA expression of two ligands, as measured by quantitative RT-PCR. EGFR expression was assessed by western blot analysis. RESULTS: There was a good correlation between the expression of four of the EGFR ligands (TGF-α, amphiregulin, epiregulin and epigen) and the growth inhibiting effect of cetuximab. TGF-α had the highest predictive potential but had to be combined with epigen for full prediction. EGFR expression also correlated with cetuximab sensitivity but less clearly. CONCLUSIONS: The results indicate that the expression of several EGFR ligands has to be used to predict sensitivity to cetuximab in HNSCC. This has to be further evaluated in clinical samples.
Authors: Takashi Yamatodani; Lars Ekblad; Elisabeth Kjellén; Anders Johnsson; Hiroyuki Mineta; Johan Wennerberg Journal: J Cancer Res Clin Oncol Date: 2008-09-24 Impact factor: 4.553
Authors: Eva Henriksson; Bo Baldetorp; Ake Borg; Elisabeth Kjellen; Jan Akervall; Johan Wennerberg; Peter Wahlberg Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: Hiromitsu Hatakeyama; Haixia Cheng; Pamela Wirth; Ashley Counsell; Samuel R Marcrom; Carey Burton Wood; Paula R Pohlmann; Jill Gilbert; Barbara Murphy; Wendell G Yarbrough; Deric L Wheeler; Paul M Harari; Yan Guo; Yu Shyr; Robbert J Slebos; Christine H Chung Journal: PLoS One Date: 2010-09-13 Impact factor: 3.240
Authors: Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro Journal: J Clin Oncol Date: 2007-08-01 Impact factor: 44.544
Authors: J B Baker; D Dutta; D Watson; T Maddala; B M Munneke; S Shak; E K Rowinsky; L-A Xu; C T Harbison; E A Clark; D J Mauro; S Khambata-Ford Journal: Br J Cancer Date: 2011-01-04 Impact factor: 7.640
Authors: Laura P Stabile; Guoqing He; Vivian Wai Yan Lui; Sufi Thomas; Cassandra Henry; Christopher T Gubish; Sonali Joyce; Kelly M Quesnelle; Jill M Siegfried; Jennifer R Grandis Journal: Clin Cancer Res Date: 2012-12-04 Impact factor: 12.531
Authors: X Qu; T Sandmann; H Frierson; L Fu; E Fuentes; K Walter; K Okrah; C Rumpel; C Moskaluk; S Lu; Y Wang; R Bourgon; E Penuel; A Pirzkall; L Amler; M R Lackner; J Tabernero; G M Hampton; O Kabbarah Journal: Oncogene Date: 2016-06-06 Impact factor: 9.867
Authors: Loredana Vesci; Ferdinando Maria Milazzo; Anna Maria Anastasi; Fiorella Petronzelli; Caterina Chiapparino; Valeria Carollo; Giuseppe Roscilli; Emanuele Marra; Laura Luberto; Luigi Aurisicchio; Maria Lucrezia Pacello; Luigi Giusto Spagnoli; Rita De Santis Journal: Oncotarget Date: 2016-01-05